Emergence of multidrug resistance among Haemophilus parainfluenzae from respiratory and urogenital samples in Barcelona, Spain.


Journal

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 03 10 2019
accepted: 20 11 2019
pubmed: 13 12 2019
medline: 11 11 2020
entrez: 13 12 2019
Statut: ppublish

Résumé

Haemophilus parainfluenzae (HPAR) is a Gram-negative bacterium that can become an opportunistic urogenital pathogen. Recently, multidrug resistant (MDR) strains have emerged. We aim to analyse the epidemiology of HPAR at Hospital Universitari de Bellvitge between 2013 and 2017 to determine its putative role in sexually transmitted infections (STI). Strains were classified by sample origin, and antimicrobial susceptibility was performed by disk-diffusion tested on Mueller-Hinton Fastidious. MDR was defined as the resistance of the antimicrobial to three or more antibiotic class. Molecular typing was performed by pulsed-field gel electrophoresis (PFGE) after restriction with SmaI and Cfr9I. We classified 944 HPAR isolates as being of urogenital (n = 175; 18.5%), respiratory (n = 719; 76.2%), or other (n = 50; 5.3%) origins. Among the urogenital isolates, 50 (28.6%) were MDR, which was significantly higher than that found in respiratory samples (40/719; 5.6%; p < 0.01). The frequency of MDR increased progressively among urogenital samples from 13.3% (2013) to 33.3% (2017) (r = 0.8; p = 0.035). The resistance rates for all 944 episodes were significantly higher for cotrimoxazole (51.4%), tetracycline (46.3%), chloramphenicol (28.0%), ciprofloxacin (21.1%), and ampicillin (20.6%). After PFGE, no clonal relationship was found. Clinical charts were available for 40 symptomatic patients with MDR HPAR infections presenting mostly urethritis (n = 26; 65.0%). In all cases, symptoms were treated effectively with combination therapy. Furthermore, in 10 of those patients with urethritis, MDR HPAR was the only potential pathogen to be identified. The emergence of MDR HPAR is a matter of concern, and the detection as a single pathogen highlights its putative role as cause of STI.

Identifiants

pubmed: 31828685
doi: 10.1007/s10096-019-03774-x
pii: 10.1007/s10096-019-03774-x
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

703-710

Subventions

Organisme : Instituto de Salud Carlos III
ID : PI16/00977
Organisme : CIBERES
ID : CB06/06/0037

Références

Case Rep Infect Dis. 2016;2016:3639517
pubmed: 27382494
Microb Drug Resist. 2017 Dec;23(8):935-939
pubmed: 28414572
J Antimicrob Chemother. 2013 May;68(5):1054-9
pubmed: 23335113
J Antimicrob Chemother. 2012 Aug;67(8):1858-60
pubmed: 22566592
Antimicrob Agents Chemother. 2015 Jan;59(1):461-6
pubmed: 25385097
Sex Transm Infect. 2016 Feb;92(1):29-31
pubmed: 26139207
Can J Infect Dis Med Microbiol. 2010 Spring;21(1):e20-2
pubmed: 21358875
Infect Genet Evol. 2016 Oct;44:507-509
pubmed: 27497656
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Medicine (Baltimore). 2015 May;94(18):e799
pubmed: 25950686
BMJ Case Rep. 2014 Oct 01;2014:
pubmed: 25274558
Microbiol Immunol. 2003;47(12):937-43
pubmed: 14695443
Can J Infect Dis Med Microbiol. 2016;2016:4503025
pubmed: 27516778
J Clin Microbiol. 1995 Sep;33(9):2233-9
pubmed: 7494007
Aust N Z J Obstet Gynaecol. 2006 Jun;46(3):258-60
pubmed: 16704486
Int J Antimicrob Agents. 2004 Mar;23(3):296-9
pubmed: 15164972
BMC Infect Dis. 2016 Aug 26;16(1):449
pubmed: 27562460
Antimicrob Agents Chemother. 2013 Jun;57(6):2867-9
pubmed: 23545526
Med Mal Infect. 2017 Feb;47(1):58-60
pubmed: 27765477
Antimicrob Agents Chemother. 1985 Aug;28(2):176-80
pubmed: 3879658
Lab Med. 2017 Feb;48(1):e1-e3
pubmed: 28039378
Microb Drug Resist. 2017 Sep;23(6):667-673
pubmed: 28103180
Gastroenterol Hepatol. 2017 Jan;40(1):23-24
pubmed: 26774675
J Antimicrob Chemother. 2008 Mar;61(3):509-14
pubmed: 18245789
J Antimicrob Chemother. 2011 Mar;66(3):673-5
pubmed: 21127039
Eur J Clin Microbiol Infect Dis. 2004 Jan;23(1):46-8
pubmed: 14669072
J Infect. 2011 Dec;63(6):474-6
pubmed: 21871487
Microb Drug Resist. 2016 Jun;22(4):247-52
pubmed: 26683319
J Bone Jt Infect. 2017 Jan 20;2(2):104-106
pubmed: 28540145
AJP Rep. 2015 Oct;5(2):e188-92
pubmed: 26495182
Thorax. 2000 Jul;55(7):623-4
pubmed: 10856326
J Microbiol Immunol Infect. 2015 Aug;48(4):450-2
pubmed: 23357607
Int J Antimicrob Agents. 2017 Feb;49(2):265-266
pubmed: 27986332
J Bacteriol. 1985 Jan;161(1):72-9
pubmed: 2981812
New Microbiol. 2009 Apr;32(2):213-5
pubmed: 19579703
J Clin Med Res. 2017 Jan;9(1):71-73
pubmed: 27924179
J Med Microbiol. 2013 May;62(Pt 5):792-793
pubmed: 23412773
Clin Rheumatol. 2015 Apr;34(4):811-4
pubmed: 24584486

Auteurs

Yanik Sierra (Y)

Microbiology Department, Hospital Universitari de Bellvitge, Feixa Llarga s/n, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.

Aida González-Díaz (A)

Microbiology Department, Hospital Universitari de Bellvitge, Feixa Llarga s/n, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.
Research Network for Respiratory Diseases (CIBERES), ISCIII, Madrid, Spain.

Fe Tubau (F)

Microbiology Department, Hospital Universitari de Bellvitge, Feixa Llarga s/n, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.
Research Network for Respiratory Diseases (CIBERES), ISCIII, Madrid, Spain.

Arkaitz Imaz (A)

Infectious Diseases Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain.

Meritxell Cubero (M)

Microbiology Department, Hospital Universitari de Bellvitge, Feixa Llarga s/n, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.
Research Network for Respiratory Diseases (CIBERES), ISCIII, Madrid, Spain.

Jordi Càmara (J)

Microbiology Department, Hospital Universitari de Bellvitge, Feixa Llarga s/n, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.
Research Network for Respiratory Diseases (CIBERES), ISCIII, Madrid, Spain.

Josefina Ayats (J)

Microbiology Department, Hospital Universitari de Bellvitge, Feixa Llarga s/n, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.

Sara Martí (S)

Microbiology Department, Hospital Universitari de Bellvitge, Feixa Llarga s/n, L'Hospitalet de Llobregat, 08907, Barcelona, Spain. smartinm@bellvitgehospital.cat.
Research Network for Respiratory Diseases (CIBERES), ISCIII, Madrid, Spain. smartinm@bellvitgehospital.cat.

Carmen Ardanuy (C)

Microbiology Department, Hospital Universitari de Bellvitge, Feixa Llarga s/n, L'Hospitalet de Llobregat, 08907, Barcelona, Spain. c.ardanuy@bellvitgehospital.cat.
Research Network for Respiratory Diseases (CIBERES), ISCIII, Madrid, Spain. c.ardanuy@bellvitgehospital.cat.
Deptartment of Pathology and Experimental Therapeutics, School of Medicine, University of Barcelona, Barcelona, Spain. c.ardanuy@bellvitgehospital.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH